Designing new drugs to treat MS - MS Research Australia

Designing new drugs to treat MS

Associate Professor Richard Hughes

The University of Melbourne, VIC

| A cure via repair and regeneration | Epidemiology | Genetics | Neurobiology | Project | 2017 | Investigator Led Research |
SUPPORT PROJECTS WITH THIS RESEARCH FOCUS

Summary

MS results from the loss of myelin, the insulating sheath around nerve fibres, in the brain and spinal cord. Brain-derived neurotrophic factor (BDNF) is one of the proteins that controls the growth of myelin during development and is also able to repair myelin after it has been damaged. As such, BDNF could form the basis of a new treatment option to repair myelin in MS. However, since BDNF is a large protein and is broken down by the body very quickly, it cannot itself be used directly as a treatment.

In an attempt to overcome these limitations, Associate Professor Hughes and his team are developing smaller molecules which mimic the function of BDNF but might also be suitable as therapies.  Associate Professor Hughes and his team were previously funded by an MS Research Australia Incubator Grant to develop a synthesis method for a compound called ‘TDP6’, which mimics BDNF and is able to repair myelin.

This project is further investigating the precise way that TDP6 repairs myelin and also determining the chemical and pharmacological profile of TDP6, important further steps in turning TDP6 into a drug for treatment. They also plan to make improvements to the current TDP6 design which will make the compound smaller and more potent. The team will also develop other mimics of BDNF for further investigation as a treatment option for MS.

Repair of myelin damage is the holy grail of MS research, as treatments which promote repair would be able to restore function that has been lost and provide therapeutic options for people with progressive forms of the disease.

Progress to Date

Associate Professor Hughes and his team have redesigned the TDP6 molecule to improve its structure. Using a cutting edge chemistry technique and using it in a completely new way, they substituted some of the molecular components of the compound with more efficient chemical connections. This will make this version of TDP6 a more effective as a treatment for MS and also considerably refine and simplify the synthesis process for TDP6, an important consideration if it is to be scaled up as a therapy for MS. In addition to the design and synthesis, tests are being undertaken to compare the actions of the new versions of TDP6 in biological pathways and compare them to the original.

Since this is a completely novel use of the chemistry, follow up work is now underway to determine the details of the chemical reaction for the scientific community, so that this technique can be used by other medicinal chemists for other applications outside of MS.

The work has underpinned a PhD project and formed part of the work undertaken by two postdoctoral researchers. This research was also leveraged to acquire a grant for $250,000 for equipment that is needed to produce and purify the peptides used in these experiments.

Publications

  • Fletcher JL, Wood RJ, Nguyen J, Norman EML, Jun CMK, Prawdiuk AR, Biemond M, Nguyen HTH, Northfield SE, Hughes RA, Gonsalvez DG, Xiao J & Murray SS. “Targeting TrkB with a brain-derived neurotrophic factor mimetic promotes myelin repair in the brain.” Journal of Neuroscience, (2018), 38 (32) 7088-7099.

Updated: 31 March 2019

Updated: 05 March, 2017

Investigator

Co-investigator

Grant Awarded

  • Project Grant

Total Funding

  • $165,000

Duration

  • 3 years over 2017 - 2019

Funding Partner

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search